A pricing analysis of cardiovascular and blood products after privatization of drug distribution system in Malaysia

Journal of Pharmaceutical Finance, Economics and Policy

Volumn 14, Issue 3, 2005, Pages 3-25

  Babar, Zaheer Ud Din ^a   Ibrahim, Mohamed Izham Mohamed ^b   Bukhari, Nadeem Irfan ^c  

^a UCSI UNIVERSITY   (Malaysia)

^b SCHOOL OF PHYSICS   (Malaysia)

^c INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

Author keywords

Blood products; Cardiovascular; Drug prices; International reference prices; Privatization

Indexed keywords

ACETAZOLAMIDE; AMILORIDE; ANTIARRHYTHMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLOROTHIAZIDE; CYANOCOBALAMIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DIURETIC AGENT; DOBUTAMINE; FERROUS FUMARATE; FUROSEMIDE; GEMFIBROZIL; HEPARIN; IRON DEXTRAN; ISOSORBIDE DINITRATE; LIDOCAINE; MANNITOL; METHYLDOPA; PHYTOMENADIONE; RECOMBINANT ERYTHROPOIETIN; SIMVASTATIN; SPIRONOLACTONE; STREPTOKINASE; UNINDEXED DRUG; VASODILATOR AGENT;

BLOOD; COST CONTROL; DRUG COST; ECONOMIC ASPECT; MALAYSIA; ORGANIZATION AND MANAGEMENT; PRIORITY JOURNAL; REVIEW;

EID: 33744959706     PISSN: 15385698     EISSN: 15385396     Source Type: Journal    
DOI: 10.1300/J371v14n03_02     Document Type: Review

References (42)

1. Ahmad M., Bukhari N. I. Pharmaceutical Management and Marketing. Tariq Academy, Faisalabad, Pakistan 2002.
2. Alavi R. TRIPS and Pharmaceuticals, The impact on Malaysian consumers. ERA Consumer Malaysia, April 2003.
3. Azmi I. M. and Alavi R. TRIPS, patents, technology transfer, foreign direct investment and the pharmaceutical industry in Malaysia. The Journal of World Intellectual Property. 4(6); 2001.
4. Babar Z. U., Izham M. Ibrahim M., Harpal S., Bukhari N. I. A Survey of Medicine Prices in Malaysia by Using WHO/HAI Methodology. Research Report, UCSI-USM, 2005 (Unpublished report).
5. Babar Z., Ibrahim M. Izham M., Bukhari N. I. Effect of privatization of drug distribution system on the prices of anti-infectives in Malaysia. Journal of Pharmaceutical Finance, Economics and Policy. 13(2); 2004.
6. Bachynsky J. A. Govt control of drug prices in Canada. Proceeding of the conference sponsored by Institute for Pharmaceutical Economics, Philadelphia College of Pharmacy & Science. Philadelphia. Sep, 1991 pg. 48-49.
7. Bala K., Lanza O. & Kaur S. R. Retail Drug Prices: Law of the Jungle in HAI News No. 100. ii) Bala K. & Sagoo K. Patents & Prices in HAI News No. 112, April/May 2000.
8. Bloom N. and Reenen J. V. Regulating drug prices: Where do we go from here? Fiscal Studies. 19(3); 321-342, 1998.
9. CAP (Consumer Association of Penang). High cost of medical care, the money book, pg. 184-185, 2004.
10. Cruez A. F. The income will decide the amount you pay, The Star. 2004.
11. Essential drug list, WHO Model List, Department of Essential Drug and Medicine Policy, WHO. 13th edition, April, 2003.
12. Gier H. D. Financing pharmaceutical care in the Dutch Health System. Journal of Pharmaceutical Finance Economics and Policy. 12(2); 181-188; 2003.
13. Goodman & Gilman's Pharmacological Basis of Therapeutics, International Edition (10th edition) 2001.
14. Kolassa, E. M. (Mick). Prices politic, and problems - A pricing philosophy. Journal of Pharmaceutical Marketing Practice. 1(1); 21-27, 1997a.
15. Kolassa, E. M. (Mick). The growing importance of pharmaceutical pricing: The forgotten P. Journal of Pharmaceutical Marketing Practice. 1(1); 13-20, 1997b.
16. Kumar S. India to extend price controls on drugs. BMJ. 329:368; 2004.
17. Lami Li. Government overpaid for medicines, The Star, September 15, 2004.
18. Lexchin J. The siren call of new drugs. Expert Rev. Pharmacoencomics Outcomes. 3 (5), 513-515; 2003.
19. Massie R. S., Variyan A. M., Cheah S. The effect of generics on pharmaceutical patent holders. Frost & Sullivan, Market Engineering Report on the Asian Generic Pharmaceutical Market (Report 4048-52), Business Briefings: Pharmagenerics 2002. pp. 30-32.
20. McFayden, Julie E. (Ed.). International Drug Price Indicator Guide 2003. Management Sciences for Health, Boston, 2004.
21. th.htm
22. Mohanta G. P., Manna P. K., Manavalan R. Medicine pricing need for an effective mechanism. Express Pharma Plus. Available at http://www. expresspharmapulse. com/20040513/editorial02.shtml; 13th May, 2004.
23. Netto A. Doctors buck privatisation of healthcare. Asia Times. June 19, 1999.
24. New Strait Times. Hospital drugs to cost more, December 4, 2004
25. Ng L. K. The Law of Medicinal Drug Regulating Safety, Efficacy, Quality and Pricing, L.L.B. thesis, University of Malaya, Kuala Lumpur, 1994. pp. 119.
26. Pascale B., Christopher G., Hoen E. T. Drugs patent under the spotlight, sharing practical knowledge about pharmaceutical patents. Medicines Sans Frontiers, 2003.
27. PCHRD (Philippine Council for Health Research and Development). Studies reveal medicines more expensive in the Philippines than in other countries 2003. Available at: www.pchrd.dost.gov.ph/PCHRD/PublicInterest/pressreleases/ drugpricing.htm.
28. PhAMA, (Pharmaceutical Association of Malaysia) booklet. First edition 2002.
29. Piong J. MPS compulsory Government Service Forum 27th September 2003.i bulletin 040121. Available at www.mps.org.my
30. Raj C. Staunching the Brain Bleed. Malaysian Business May 1, 2000 (ISSN 0126-5504) pp. 38-39. Available at: www2.jarring.my/pcdom/mybizsbb.htm.
31. Razak A.D. Going generic and bringing health to all, in New Strait Times, Jun 25, 1998 pg. 12.
32. Sirkia T. & Rajaniemi S. Country Report Finland Pharmaceutical Pricing and reimbursement policies. LSE health. Pharmaceutical Pricing Board and Social Insurance Institution, 2003.
33. Spilker B. Multinational drug companies, Raven Press, NY 1989
34. The Malaysian Trade Classification and Customs Duties Order, 1999.
35. The Star, Govt factor plays big part, August 7, 2004.
36. The Star, Malaysia, April 24, 1993.
37. The Star, Ministry list not finalized yet, June 5, 2004b.
38. Vernon J.A. Drug Research and Price Controls. Regulation winter; 22-25, 2002-2003.
39. Weitzel V. Vietnamese authorities admit loose control over pharmaceutical prices, Health-Vn. 18 March 2003. Available at: http://www.undp.org.vn/mlist/ health/032003/post42.htm.
40. Wertheimer A. I. and Grumer S. K. Overview of international pharmacy pricing. PharmacoEconomics. 2 (6); 449-455, 1992.
41. WHO-WPRO (Western Pacific Regional Office), Malaysia-Western Pacific Region Health Data Bank, Manila. Revised/November, 2002.
42. WHO-WTO Secretaries, Report of the workshop on differential pricing and financing of essential drugs. Norwegian Foreign Affairs Ministry, Global Health Council, Norway, April 8-11 2001.